On 6 June 2026, INOVIQ expanded the platform into ovarian cancer, reporting positive in vitro proof-of-concept data across three ovarian cancer cell lines. CA125-targeted CAR-exosomes achieved more than 90% tumour cell killing in OVCAR-3 and Caov-3 cell lines within 48 hours, while EGFR-targeted CAR-exosomes achieved more than 80% tumour cell killing in the same models. In the highly aggressive and treatmentresistant SK-OV-3 cell line, both approaches achieved approximately 50% tumour cell killing. INOVIQ’s CAR-exosome platform has now demonstrated in vitro tumour-killing activity across multiple hard-to-treat cancers, including TNBC, non-small cell lung cancer (NSCLC) and ovarian cancer. In FY27 the Company is advancing preclinical development and manufacturing readiness through GMPcompliant cell sourcing, CDMO selection and optimisation of next-generation dualaction CAR-exosomes designed to enhance tumour targeting and overcome the tumour microenvironment. These activities support INOVIQ’s pathway toward first-in-human (FIH) studies targeted for 2028. SUBB2M DIAGNOSTICS FOR CANCER MONITORING neuCA15-3 is a blood test in development for monitoring breast cancer in women. The assay combines a CA15-3 monoclonal antibody with INOVIQ’s proprietary SubB2M technology to more specifically detect tumour-derived CA153, potentially improving accuracy and reducing false positives. The test has demonstrated analytical and clinical performance, achieving 81% sensitivity and 93% specificity across all stages of breast cancer, major disease subtypes and post-treatment monitoring settings. INOVIQ is advancing neuCA15-3 to a bead-based chemiluminescent assay compatible with highthroughput automated laboratory platforms to enhance commercial scalability and laboratory implementation. Following assay optimisation and validation, the Company intends to undertake additional clinical validation studies to support commercial partnering opportunities. The next steps to commercialise the neuCA15-3 test include completing transfer to a highthroughput instrument platform, additional in-clinic breast cancer monitoring study and securing a partner for commercialisation. Review of Operations continued COMMERCIAL UPDATE Commercial activities during the year focused on EXONET customer engagement, expanding evaluations and collaborative partnerships. EXO-NET® EXOSOME ISOLATION EXO-NET® is INOVIQ’s proprietary capture technology used to isolate exosomes from body fluids offering speed, specificity and scalability advantages over conventional methods. The technology is commercially available worldwide through INOVIQ’s global distribution partner, Promega Corporation. Promega grew the EXO-NET customer base to 90 by year-end across academic/government institutes, biopharma companies and clinical laboratories/hospitals. Customer adoption was strongest in Europe, followed by North America and Asia-Pacific, with applications spanning fundamental EV research, biomarker discovery and diagnostic development. EXO-NET revenues achieved $138,045 for FY2026 (2025: $253,261). The decrease reflects the timing of inventory management within the distribution channel following stronger customer purchasing activity in the prior year. INOVIQ continues to engage with academia and industry partners to expand collaborations and commercial opportunities for EXO-NET, NEURO-NET and customNET products. Multiple evaluations were progressed for biomarker discovery and diagnostic development across cancer, cardiology and neurological diseases. Successful conversion of these evaluations, together with advancement of customer diagnostic programs, is expected to support future product sales and longerterm commercial growth. HTERT ICC TEST The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. The hTERT test is registered as an IVD medical device in the United States (Class I IVD) for use as a clinical diagnostic by pathology laboratories for the detection of hTERT in cytopathology samples11. The hTERT test is sold direct to laboratory customers in the US achieving revenues of $294,002 during the year (2025: $294,314). hTERT revenue is expected to remain flat in FY2027 due to the limited market size and increased competition from new products. 11 Allison et al. Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens. Acta Cytologica 2018. DOI: 10.1159/000489181 10 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3